Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EGFR and HER2 signals play a salvage role in MEK1-mutated gastric cancer after MEK inhibition.

International journal of oncology - 1 Aug 2015

Mizukami Takuro, Togashi Yosuke, Sogabe Shunsuke, Banno Eri, Terashima Masato, De Velasco Marco A, Sakai Kazuko, Fujita Yoshihiko, Tomida Shuta, Nakajima Takako Eguchi, Boku Narikazu, Nishio Kazuto

Abstract excerpt

Since the prognosis of unresectable advanced gastric cancer remains poor, novel therapeutic strategies are needed. Somatic MEK1 gene mutations have been reported as oncogenic activating mutations in gastric cancer, and MEK inhibitors can be effective against such gastric cancers. In the present study, however, activated EGFR and HER2 signals after treatment with a MEK inhibitor (trametinib) were found in a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Synergism
Share to Lapatinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to MAP Kinase Kinase 1

Share to MAP Kinase Signaling System

Share to Pyridones

Share to Pyrimidinones

Share to Quinazolines

Share to Receptor, ErbB-2

Source

Identifiers

PMID: 26081723
DOI: 10.3892/ijo.2015.3050

Genes

EGFR
EGF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EGFR and HER2 signals play a salvage role in MEK1-mutated gastric cancer after MEK inhibition.PMID 26081723Read ↗

MEK inhibitor for gastric cancer with MEK1 gene mutations.Semantic proximity Read ↗

Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cellsSemantic proximity Read ↗

Trametinib in the treatment of multiple malignancies harboring MEK1 mutations.Semantic proximity Read ↗

A novel treatment strategy for lapatinib resistance in a subset of HER2-amplified gastric cancerSemantic proximity Read ↗

FOXO1 Suppression is a Determinant of Acquired Lapatinib-Resistance in HER2-Positive Gastric Cancer Cells Through MET UpregulationSemantic proximity Read ↗

Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancerSemantic proximity Read ↗

A Novel c-Met/TRK inhibitor 1D228 efficiently inhibits tumor growth by targeting angiogenesis and tumor cell proliferation.Semantic proximity Read ↗

Gastric cancer patient with c-MET amplification treated with crizotinib after failed multi-line treatment: A case report and literature reviewSemantic proximity Read ↗

Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibitionSemantic proximity Read ↗

Cetuximab combined with FOLFOX4 as the first-line treatment for advanced gastric cancer: report of 25 cases from a single institution.Semantic proximity Read ↗

Reduced phosphorylation of ribosomal protein S6 is associated with sensitivity to MEK inhibition in gastric cancer cellsSemantic proximity Read ↗

Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.